DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials (Q85047234)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

14 February 2020

title

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

14 February 2020

main subject

phase I clinical trial

1 reference

1 reference

12

Terrence M Tumpey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

14 February 2020

15

Gary J Nabel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

14 February 2020

8

Melissa B Pearce

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

14 February 2020

16

Barney S Graham

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

14 February 2020

1

Julie E Ledgerwood

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

14 February 2020

5

Mary E Enama

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

14 February 2020

14

John R Mascola

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

14 February 2020

4

Ingelise J Gordon

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

14 February 2020

13

Richard A Koup

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

14 February 2020

6

Cynthia S Hendel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

14 February 2020

9

Hadi M Yassine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

14 February 2020

10

Jeffrey C Boyington

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

14 February 2020

2

Chih-Jen Wei

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

14 February 2020

7

Patrick M McTamney

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Zonghui Hu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

14 February 2020

Robert Bailer

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

14 February 2020

VRC 306 Study Team

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

14 February 2020

Julie E. Ledgerwood

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21975270

13 December 2024

Gary J. Nabel

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21975270

13 December 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21975270

13 December 2024

publication date

3 October 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

full work available at URL

14 February 2020

http://www.thelancet.com/article/S1473309911702407/pdf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21975270

https://europepmc.org/articles/PMC7185472

13 December 2024

file format

HyperText Markup Language

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21975270

https://europepmc.org/articles/PMC7185472?pdf=render

13 December 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21975270

https://api.elsevier.com/content/article/PII:S1473309911702407?httpAccept=text/xml

13 December 2024

1 reference

10.1016/S1473-3099(11)70240-7

Crossref

DOI

https://api.crossref.org/works/10.1016/S1473-3099(11)70240-7

https://api.elsevier.com/content/article/PII:S1473309911702407?httpAccept=text/plain

13 December 2024

1 reference

10.1016/S1473-3099(11)70240-7

Crossref

DOI

https://api.crossref.org/works/10.1016/S1473-3099(11)70240-7

Lancet Infectious Diseases

13 December 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

14 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

14 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

916-924

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975270 AND SRC:MED&resulttype=core&format=json

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

14 February 2020

cites work

1 reference

12 December 2020

Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin

1 reference

12 December 2020

Antibody recognition of a highly conserved influenza virus epitope

1 reference

12 December 2020

Vaccines for pandemic influenza

1 reference

12 December 2020

A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial

1 reference

12 December 2020

Induction of broadly neutralizing H1N1 influenza antibodies by vaccination

1 reference

12 December 2020

Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies

1 reference

12 December 2020

A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains

1 reference

12 December 2020

Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design

1 reference

12 December 2020

The origins of pandemic influenza--lessons from the 1918 virus.

1 reference

12 December 2020

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial

1 reference

12 December 2020

Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009.

1 reference

12 December 2020

Variation and infectivity neutralization in influenza

1 reference

12 December 2020

Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant

1 reference

12 December 2020

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

1 reference

12 December 2020

DNA vaccines: a safe and efficient platform technology for responding to emerging infectious diseases

1 reference

12 December 2020

Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans

1 reference

12 December 2020

Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies

1 reference

12 December 2020

A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).

1 reference

12 December 2020

Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine

1 reference

12 December 2020

Determinants of immunity to influenza infection in man

1 reference

12 December 2020

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa

1 reference

12 December 2020

Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine

1 reference

12 December 2020

Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens

1 reference

12 December 2020

Human infection with a triple-reassortant swine influenza A(H1N1) virus containing the hemagglutinin and neuraminidase genes of seasonal influenza virus.

1 reference

12 December 2020

Influenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferrets

1 reference

12 December 2020

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

1 reference

12 December 2020

Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine

1 reference

12 December 2020

Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects

1 reference

12 December 2020

Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses.

1 reference

12 December 2020

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial

1 reference

12 December 2020

Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity

1 reference

12 December 2020

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

1 reference

12 December 2020

A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial

1 reference

12 December 2020